Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

ABSTRACT:

Introduction

Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population?

Materials and methods

Patients were identified from the three French hematological malignancies population-based registries. All CML patients (ICD-O-3: 9875/3) diagnosed between 2006 and 2016 and resided in registries areas were included. The TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis. An alluvial plot described the pathways leading to death.

Results

In total, 507 CML patients received TKI in first-line treatment, 22% were enrolled in a c

SUBMITTER: Canet J 

PROVIDER: S-EPMC8525157 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature